MDWD MediWound

MediWound to Report Third Quarter 2025 Financial Results

MediWound to Report Third Quarter 2025 Financial Results

MediWound to Report Third Quarter 2025 Financial Results

Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time

YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2025 on Thursday, November 20, 2025.

Following the release, the Company’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.

Dial-in and call details are as follows:

Conference Call & Webcast Details

Toll-Free:                1-844-676-8833

Israel:                     1-809-212373

International:          1-412-634-6869

Webcast:                

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity.

For more information, visit and follow us on and .

MediWound Contacts:                                                Media Contact:

Hani Luxenburg                            Daniel Ferry                                 Ellie Hanson

Chief Financial Officer                  Managing Director                       Partner

MediWound Ltd.                           LifeSci Advisors, LLC                   FINN Partners for MediWound

                               



EN
05/11/2025

Underlying

MDWDMediWound

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediWound

 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Files Annual Report on Form 20-F

MediWound Files Annual Report on Form 20-F MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on March 5, 2026. The annual report can be accessed on the SEC’s website at , as well as via the Company’s investor relations website at . The Company will provide a hard copy of its annual report o...

March 5, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results

MediWound Reports Fourth Quarter and Full Year 2025 Financial Results EscharEx® Phase III VALUE trial advancing as planned Expanded NexoBrid® manufacturing facility operational; regulatory approvals expected in 2026 $17 million revenue in 2025; $54 million in cash at year-end; 2026–2028 revenue guidance reaffirmed Conference Call Today, March 5, 2026, at 8:30 a.m. Eastern Time YAVNE, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for...

March 5, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound to Report Fourth Quarter and Full Year 2025 Financial Result...

MediWound to Report Fourth Quarter and Full Year 2025 Financial Results MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 5, 2026. Following the release, MediWound’s management will host a conference ca...

February 19, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound to Present at Upcoming Investor Conferences

MediWound to Present at Upcoming Investor Conferences MediWound to Present at Upcoming Investor Conferences YAVNE, Israel, February 17, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that its management team will present at the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 Time: 10:40 a.m. ET Location: Virtual Webcast: TD Cowen 46th Annual Health Care Conference Date: Monday, March 2, 2026 Time: 1:10 p.m. ET ...

February 17, 2026 1 EN
 PRESS RELEASE
Free
MDWD MEDIWOUND

MediWound Provides Corporate Update and Financial Outlook Ahead of the...

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx® VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to diabetic foot ulcers (DFUs) and pressure ulcers (PUs) anticipated in 2026 Expanded NexoBrid® manufacturing facility fully operational; regulatory approvals targeted for 2026 $17 million in 2025 revenue; financial guidance updated...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch